Teva Pharmaceutical Industries Ltd. $TEVA Shares Bought by WCM Investment Management LLC

by · The Cerbat Gem

WCM Investment Management LLC increased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) by 0.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 214,756 shares of the company’s stock after purchasing an additional 1,599 shares during the quarter. WCM Investment Management LLC’s holdings in Teva Pharmaceutical Industries were worth $3,599,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in TEVA. Golden State Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $39,000. New Age Alpha Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $43,000. Sound Income Strategies LLC increased its holdings in shares of Teva Pharmaceutical Industries by 3,715.8% in the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after purchasing an additional 2,824 shares in the last quarter. Banque Cantonale Vaudoise purchased a new position in shares of Teva Pharmaceutical Industries in the 1st quarter valued at about $74,000. Finally, Brooklyn Investment Group increased its holdings in shares of Teva Pharmaceutical Industries by 403.4% in the 1st quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock valued at $77,000 after purchasing an additional 4,014 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on TEVA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Finally, JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Buy” and an average target price of $25.57.

Read Our Latest Report on TEVA

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 0.8%

Shares of NYSE TEVA opened at $19.62 on Friday. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a market capitalization of $22.50 billion, a PE ratio of -122.63, a price-to-earnings-growth ratio of 1.09 and a beta of 0.71. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The firm’s 50-day moving average is $18.83 and its two-hundred day moving average is $17.07.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company’s quarterly revenue was up .3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

(Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Featured Articles